313
Participants
Start Date
May 31, 2006
Primary Completion Date
September 30, 2007
Study Completion Date
December 31, 2007
NicVAX conjugate vaccine
200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
Placebo
Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
Department of Public & Community Health, College Park
University of Wisconsin, Madison
University of Minnesota, Minneapolis
University of Nebraska Medical Center, Omaha
David Geffen School of Medicine at UCLA, Los Angeles
University of California, San Francisco
Oregon Health & Science University, Portland
University of Connecticut Health Center, Farmington
Tobacco Research Center, Massachusetts General Hospital, Boston
Collaborators (1)
Nabi Biopharmaceuticals
INDUSTRY
National Institute on Drug Abuse (NIDA)
NIH